From: Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers
Treatment | Gene name | Genotype | |
---|---|---|---|
WT | CAR -/- | ||
TCPOBOP | Hmgcr | 2.22 ± 1.38 | 0.35 ± 0.18* |
Sqle | 2.18 ± 1.1* | 0.69 ± 0.25* | |
Cyp51a1 | 1.43 ± 0.89 | 0.43 ± 0.16* | |
Insig1 | 1.86 ± 0.77 | 0.55 ± 0.24* | |
Srebp2 | 1.31 ± 0.73 | 0.49 ± 0.20* | |
Cyp3a11 | 5.82 ± 3.35* | 0.44 ± 0.36 | |
Cyp2b10 | 5750 ± 2805* | 3.59 ± 5.61 | |
Untreated CAR -/- vs WT | Hmgcr | - | 4.1 ± 1.26* |
Sqle | - | 2.90 ± 0.55* | |
Cyp51a1 | - | 2.81 ± 0.74* | |
Insig1 | - | 3.38 ± 1.02* | |
Srebp2 | - | 3.95 ± 1.14* | |
Cyp3a11 | - | 3.03 ± 1.80 | |
Cyp2b10 | - | 0.76 ± 0.54 |